C. Emily Kleinrouweler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
C. Emily Kleinrouweler has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Eva Pajkrt
Department of Obstetrics and Gynaecology, Academic Medical Center, Amsterdam, The Netherlands
3 shared publications - Ben Willem Mol
Department of Obstetrics and Gynaecology Monash University Clayton Victoria Australia
2 shared publications - Jeanine van der Ven
Department of Obstetrics and Gynecology, Academic Medical Center, Amsterdam, The Netherlands
2 shared publications - Melanie A van Os
Department of Obstetrics and Gynaecology, VU Medical Centre, Amsterdam, The Netherlands
2 shared publications - Monique C. Haak
Department of Obstetrics and Gynecology Leiden University Medical Center Leiden the Netherlands
2 shared publications A. E. Diab
Zagazig Faculty of Medicine; Department of Obstetrics and Gynaecology; Zagazig, Ash Sharqiyah; Egypt
1 shared publication
Latest Publications
- 1 January 2016
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 214 (1) , 79-90.e36
Prognostic models in obstetrics: available, but far from applicable
- 1 January 2016
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 214 (1) , 79-90.e36
Prognostic models in obstetrics: available, but far from applicable
- 1 May 2015
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 188, 12-16
Is cervical length associated with maternal characteristics?
- 1 May 2015
- Published by Elsevier in European Journal of Obstetrics & Gynecology and Reproductive Biology
- Vol. 188, 12-16
Is cervical length associated with maternal characteristics?
- Open Access
- 25 August 2014
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 44 (3) , 249-251
Clinical prediction models for pre-eclampsia: time to take the next step
- 25 August 2014
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 44 (3) , 249-251
Open AccessClinical prediction models for pre-eclampsia: time to take the next step
- 6 August 2013
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 42 (3) , 257-267
Value of adding second-trimester uterine artery Doppler to patient characteristics in identification of nulliparous women at increased risk for pre-eclampsia: an individual patient data meta-analysis
Not availableC. E. Kleinrouweler, P. M. M. Bossuyt, B. Thilaganathan, K. C. Vollebregt, J. Arenas Ramrez, A. Ohkuchi, K. L. Deurloo, M. Macleod, A. E. Diab, H. Wolf, J. A. M. van der Post, B. W. J. Mol and E. Pajkr
- 6 August 2013
- Published by Wiley in Ultrasound in Obstetrics & Gynecology
- Vol. 42 (3) , 257-267
Value of adding second-trimester uterine artery Doppler to patient characteristics in identification of nulliparous women at increased risk for pre-eclampsia: an individual patient data meta-analysis
Not availableC. E. Kleinrouweler, P. M. M. Bossuyt, B. Thilaganathan, K. C. Vollebregt, J. Arenas Ramrez, A. Ohkuchi, K. L. Deurloo, M. Macleod, A. E. Diab, H. Wolf, J. A. M. van der Post, B. W. J. Mol and E. Pajkr
- 20 March 2012
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 119 (7) , 778-787
Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms‐like tyrosine kinase 1 and soluble endoglin in the prediction of pre‐eclampsia: a systematic review and meta‐analysis
Please cite this paper as: Kleinrouweler C, Wiegerinck M, Ris‐Stalpers C, Bossuyt P, van der Post J, von Dadelszen P, Mol B, Pajkrt E, for the EBM CONNECT Collaboration. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms‐like tyrosine kinase 1 and soluble endoglin in the prediction of pre‐eclampsia: a systematic review and meta‐analysis. BJOG 2012;119:778–787.Background Biomarkers have been proposed for identification of women at increased risk of developing pre‐eclampsia.Objectives To investigate the capacity of circulating placental growth factor (PlGF), vascular endothelial growth factor (VEGF), soluble fms‐like tyrosine kinase‐1 (sFLT1) and soluble endoglin (sENG) to predict pre‐eclampsia.Search strategy Medline and Embase through October 2010 and reference lists of reviews, without constraints.Selection criteria We included original publications on testing of PlGF, VEGF, sFLT1 and sENG in serum or plasma of pregnant women at Data collection and analysis Two reviewers independently identified eligible studies, extracted descriptive and test accuracy data and assessed methodological quality. Summary estimates of discriminatory performance were obtained.Main results We included 34 studies. Concentrations of PlGF (27 studies) and VEGF (three studies) were lower in women who developed pre‐eclampsia: standardised mean differences (SMD) −0.56 (95% CI −0.77 to −0.35) and −1.25 (95% CI −2.73 to 0.23). Concentrations of sFLT1 (19 studies) and sENG (ten studies) were higher: SMD 0.48 (95% CI 0.21–0.75) and SMD 0.54 (95% CI 0.24–0.84). The summary diagnostic odds ratios were: PlGF 9.0 (95% CI 5.6–14.5), sFLT1 6.6 (95% CI 3.1–13.7), sENG 4.2 (95% CI 2.4–7.2), which correspond to sensitivities of 32%, 26% and 18%, respectively, for a 5% false‐positive rate.Author’s conclusions PlGF, sFLT1 and sENG showed modest but significantly different concentrations before 30 weeks of gestation in women who developed pre‐eclampsia. Test accuracies of all four markers, however, are too poor for accurate prediction of pre‐eclampsia in clinical practice.
- 20 March 2012
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 119 (7) , 778-787
Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms‐like tyrosine kinase 1 and soluble endoglin in the prediction of pre‐eclampsia: a systematic review and meta‐analysis
Please cite this paper as: Kleinrouweler C, Wiegerinck M, Ris‐Stalpers C, Bossuyt P, van der Post J, von Dadelszen P, Mol B, Pajkrt E, for the EBM CONNECT Collaboration. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms‐like tyrosine kinase 1 and soluble endoglin in the prediction of pre‐eclampsia: a systematic review and meta‐analysis. BJOG 2012;119:778–787.Background Biomarkers have been proposed for identification of women at increased risk of developing pre‐eclampsia.Objectives To investigate the capacity of circulating placental growth factor (PlGF), vascular endothelial growth factor (VEGF), soluble fms‐like tyrosine kinase‐1 (sFLT1) and soluble endoglin (sENG) to predict pre‐eclampsia.Search strategy Medline and Embase through October 2010 and reference lists of reviews, without constraints.Selection criteria We included original publications on testing of PlGF, VEGF, sFLT1 and sENG in serum or plasma of pregnant women at Data collection and analysis Two reviewers independently identified eligible studies, extracted descriptive and test accuracy data and assessed methodological quality. Summary estimates of discriminatory performance were obtained.Main results We included 34 studies. Concentrations of PlGF (27 studies) and VEGF (three studies) were lower in women who developed pre‐eclampsia: standardised mean differences (SMD) −0.56 (95% CI −0.77 to −0.35) and −1.25 (95% CI −2.73 to 0.23). Concentrations of sFLT1 (19 studies) and sENG (ten studies) were higher: SMD 0.48 (95% CI 0.21–0.75) and SMD 0.54 (95% CI 0.24–0.84). The summary diagnostic odds ratios were: PlGF 9.0 (95% CI 5.6–14.5), sFLT1 6.6 (95% CI 3.1–13.7), sENG 4.2 (95% CI 2.4–7.2), which correspond to sensitivities of 32%, 26% and 18%, respectively, for a 5% false‐positive rate.Author’s conclusions PlGF, sFLT1 and sENG showed modest but significantly different concentrations before 30 weeks of gestation in women who developed pre‐eclampsia. Test accuracies of all four markers, however, are too poor for accurate prediction of pre‐eclampsia in clinical practice.
- Open Access
- 24 October 2011
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 11 (1) , 77
Preventing preterm birth with progesterone: costs and effects of screening low risk women with a singleton pregnancy for short cervical length, the Triple P study
Background: Women with a short cervical length in mid-trimester pregnancy have a higher risk of preterm birth and therefore a higher rate of neonatal mortality and morbidity. Progesterone can potentially decrease the number of preterm births and lower neonatal mortality and morbidity. Previous studies showed good results of progesterone in women with either a history of preterm birth or a short cervix. However, it is unknown whether screening for a short cervix and subsequent treatment in mid trimester pregnancy is effective in low risk women. Methods/Design: We plan a combined screen and treat study among women with a singleton pregnancy without a previous preterm birth. In these women, we will measure cervical length at the standard anomaly scan performed between 18 and 22 weeks. Women with cervical length ≤ 30 mm at two independent measurements will be randomly allocated to receive either vaginal progesterone tablets or placebo between 22 and 34 weeks. The primary outcome of this trial is adverse neonatal condition, defined as a composite outcome of neonatal mortality and severe morbidity. Secondary outcomes are time to delivery, preterm birth rate before 32, 34 and 37 weeks, days of admission in neonatal intensive care unit, maternal morbidity, maternal admission days for preterm labour and costs. We will assess growth, physical condition and neurodevelopmental outcome of the children at two years of age. Discussion: This study will provide evidence for the usefulness and cost-effectiveness of screening for short cervical length at the 18-22 weeks and subsequent progesterone treatment among low risk women. Trial registration: Netherlands Trial Register (NTR): NTR207
- 24 October 2011
- Published by Springer Nature in BMC Pregnancy and Childbirth
- Vol. 11 (1) , 77
Open AccessPreventing preterm birth with progesterone: costs and effects of screening low risk women with a singleton pregnancy for short cervical length, the Triple P study
Background: Women with a short cervical length in mid-trimester pregnancy have a higher risk of preterm birth and therefore a higher rate of neonatal mortality and morbidity. Progesterone can potentially decrease the number of preterm births and lower neonatal mortality and morbidity. Previous studies showed good results of progesterone in women with either a history of preterm birth or a short cervix. However, it is unknown whether screening for a short cervix and subsequent treatment in mid trimester pregnancy is effective in low risk women. Methods/Design: We plan a combined screen and treat study among women with a singleton pregnancy without a previous preterm birth. In these women, we will measure cervical length at the standard anomaly scan performed between 18 and 22 weeks. Women with cervical length ≤ 30 mm at two independent measurements will be randomly allocated to receive either vaginal progesterone tablets or placebo between 22 and 34 weeks. The primary outcome of this trial is adverse neonatal condition, defined as a composite outcome of neonatal mortality and severe morbidity. Secondary outcomes are time to delivery, preterm birth rate before 32, 34 and 37 weeks, days of admission in neonatal intensive care unit, maternal morbidity, maternal admission days for preterm labour and costs. We will assess growth, physical condition and neurodevelopmental outcome of the children at two years of age. Discussion: This study will provide evidence for the usefulness and cost-effectiveness of screening for short cervical length at the 18-22 weeks and subsequent progesterone treatment among low risk women. Trial registration: Netherlands Trial Register (NTR): NTR207
- 16 February 2011
- Published by S. Karger AG in Fetal Diagnosis and Therapy
- Vol. 30 (1) , 60-69
Characteristics and Outcome and the Omphalocele Circumference/Abdominal Circumference Ratio in Prenatally Diagnosed Fetal Omphalocele
Objective: To evaluate the outcome of fetuses with prenatally diagnosed omphalocele and to investigate the predictive value of the omphalocele circumference/abdominal circumference (OC/AC) ratio – a measure for the relative size of the omphalocele. Materials and Methods: This study includes all fetuses prenatally diagnosed with omphalocele at our centre between 1995 and 2007. Medical records and footage of ultrasound examinations were reviewed. Omphalocele was classified in four groups: isolated, chromosomal, syndromic, and multiple anomalies. Results: Eighty-eight cases were identified: 21 (24%) were isolated and 67 had additional structural anomalies. Of the 44 fetuses (50%) with chromosomal anomalies, 2 had omphalocele as a solitary finding. Fifty-three pregnancies (60%) were terminated because of the size of the lesion or associated structural or chromosomal anomalies. Twenty-one cases resulted in a live birth, of which 17 were vaginal deliveries (81%, all uncomplicated) including 3 cases of giant omphalocele (≧5 cm). The OC/AC ratio was found predictive for herniation of the liver, respiratory insufficiency and type of surgical reconstruction. Currently, 12/88 fetuses (14%) are alive and well, including 2 infants with multiple anomalies. Conclusion: Identification of omphalocele should arouse suspicion of genetic abnormalities, even in cases that appear isolated. The OC/AC ratio may influence counselling regarding the postnatal course.
- 16 February 2011
- Published by S. Karger AG in Fetal Diagnosis and Therapy
- Vol. 30 (1) , 60-69
Characteristics and Outcome and the Omphalocele Circumference/Abdominal Circumference Ratio in Prenatally Diagnosed Fetal Omphalocele
Objective: To evaluate the outcome of fetuses with prenatally diagnosed omphalocele and to investigate the predictive value of the omphalocele circumference/abdominal circumference (OC/AC) ratio – a measure for the relative size of the omphalocele. Materials and Methods: This study includes all fetuses prenatally diagnosed with omphalocele at our centre between 1995 and 2007. Medical records and footage of ultrasound examinations were reviewed. Omphalocele was classified in four groups: isolated, chromosomal, syndromic, and multiple anomalies. Results: Eighty-eight cases were identified: 21 (24%) were isolated and 67 had additional structural anomalies. Of the 44 fetuses (50%) with chromosomal anomalies, 2 had omphalocele as a solitary finding. Fifty-three pregnancies (60%) were terminated because of the size of the lesion or associated structural or chromosomal anomalies. Twenty-one cases resulted in a live birth, of which 17 were vaginal deliveries (81%, all uncomplicated) including 3 cases of giant omphalocele (≧5 cm). The OC/AC ratio was found predictive for herniation of the liver, respiratory insufficiency and type of surgical reconstruction. Currently, 12/88 fetuses (14%) are alive and well, including 2 infants with multiple anomalies. Conclusion: Identification of omphalocele should arouse suspicion of genetic abnormalities, even in cases that appear isolated. The OC/AC ratio may influence counselling regarding the postnatal course.